Autopsy report · NCT00113256
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Cause of deathNo reason given
Life of this trial
- Registered 4 months after it had already started.
- 39 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Astex Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Pancreatic Cancer
- Interventions
- Rubitecan
- Participants
- 39
- Sites
- 11
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.